VolitionRX Ltd Company Profile (NYSEMKT:VNRX)

About VolitionRX Ltd (NYSEMKT:VNRX)

VolitionRX Ltd logoVolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Diagnostic & Testing Substances
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:VNRX
  • CUSIP: N/A
  • Web: www.volitionrx.com/
Capitalization:
  • Market Cap: $57.81 million
  • Outstanding Shares: 26,518,000
Average Prices:
  • 50 Day Moving Avg: $2.64
  • 200 Day Moving Avg: $3.16
  • 52 Week Range: $2.11 - $5.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.82
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.63 per share
  • Price / Book: 3.46
Profitability:
  • EBITDA: ($13,230,000.00)
  • Return on Equity: -79.20%
  • Return on Assets: -63.86%
Misc:
  • Average Volume: 37,923 shs.
  • Beta: -1.58
  • Short Ratio: 3.43
 

Frequently Asked Questions for VolitionRX Ltd (NYSEMKT:VNRX)

What is VolitionRX Ltd's stock symbol?

VolitionRX Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "VNRX."

How were VolitionRX Ltd's earnings last quarter?

VolitionRX Ltd (NYSEMKT:VNRX) released its earnings results on Thursday, May, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. View VolitionRX Ltd's Earnings History.

When will VolitionRX Ltd make its next earnings announcement?

VolitionRX Ltd is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for VolitionRX Ltd.

Where is VolitionRX Ltd's stock going? Where will VolitionRX Ltd's stock price be in 2017?

1 brokerages have issued 1 year price targets for VolitionRX Ltd's shares. Their predictions range from $10.00 to $10.00. On average, they expect VolitionRX Ltd's share price to reach $10.00 in the next twelve months. View Analyst Ratings for VolitionRX Ltd.

Who are some of VolitionRX Ltd's key competitors?

Who are VolitionRX Ltd's key executives?

VolitionRX Ltd's management team includes the folowing people:

  • Martin Charles Faulkes, Executive Chairman of the Board
  • Cameron John Reynolds, President, Chief Executive Officer, Director
  • David Vanston, Chief Financial Officer, Treasurer
  • Louise Dayas, Chief Marketing and Communications Officer
  • Jason Bradley Terrell, Chief Medical Officer and Head of US Operations
  • Rodney Gerard Rootsaert, Secretary
  • Alan Colman, Director
  • Edward W. Futcher Ph.D., Independent Director
  • Guy Archibald Innes, Independent Director
  • Habib Skaff, Independent Director

How do I buy VolitionRX Ltd stock?

Shares of VolitionRX Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VolitionRX Ltd's stock price today?

One share of VolitionRX Ltd stock can currently be purchased for approximately $2.18.


MarketBeat Community Rating for VolitionRX Ltd (NYSEMKT VNRX)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about VolitionRX Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for VolitionRX Ltd (NYSEMKT:VNRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00
Consensus Price Target History for VolitionRX Ltd (NYSEMKT:VNRX)
Price Target History for VolitionRX Ltd (NYSEMKT:VNRX)
Analysts' Ratings History for VolitionRX Ltd (NYSEMKT:VNRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2017HC WainwrightReiterated RatingBuy$10.00View Rating Details
9/7/2016Rodman & RenshawLower Price TargetBuy$12.00 -> $10.00View Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for VolitionRX Ltd (NYSEMKT:VNRX)
Earnings by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Earnings History by Quarter for VolitionRX Ltd (NYSEMKT VNRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017        
5/11/20173/31/2017($0.14)($0.13)ViewN/AView Earnings Details
8/11/2016Q216($0.12)($0.13)ViewListenView Earnings Details
5/13/2016Q116($0.13)($0.13)ViewN/AView Earnings Details
11/4/2015Q315($0.13)($0.16)$0.20 millionViewN/AView Earnings Details
8/11/2015Q215($0.14)($0.10)$0.11 millionViewN/AView Earnings Details
5/12/2015Q115($0.14)($0.12)ViewN/AView Earnings Details
11/6/2014($0.09)($0.13)$0.13 million$0.02 millionViewN/AView Earnings Details
5/27/2014($0.10)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for VolitionRX Ltd (NYSEMKT:VNRX)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Dividends

Dividend History for VolitionRX Ltd (NYSEMKT:VNRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for VolitionRX Ltd (NYSEMKT:VNRX)
Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Institutional Ownership by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017David Cecil VanstonInsiderBuy2,750$2.84$7,810.00View SEC Filing  
8/16/2017Cameron John ReynoldsInsiderBuy3,630$2.77$10,055.10View SEC Filing  
10/5/2016David Matthew KratochvilCFOBuy10,000$5.00$50,000.00View SEC Filing  
5/20/2016Cameron John ReynoldsCEOSell3,390$3.54$12,000.60View SEC Filing  
5/15/2015Cameron John ReynoldsCEOBuy1,500$3.33$4,995.00View SEC Filing  
2/11/2015Guy Archibald InnesDirectorBuy50,000$3.75$187,500.00View SEC Filing  
9/15/2014Martin Charles FaulkesDirectorBuy5,000$2.16$10,800.00View SEC Filing  
9/3/2014Rodney Gerard RootsaertInsiderSell28,000$1.80$50,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for VolitionRX Ltd (NYSEMKT:VNRX)
Latest Headlines for VolitionRX Ltd (NYSEMKT:VNRX)
Source:
Loading headlines, please wait.

Social

Chart

VolitionRX Ltd (VNRX) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.